Clinical Trial: Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide Analogues

U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07933627) titled 'Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide Analogues' on Oct. 21.

Brief Summary: To evaluate the efficacy of YKYY013 in patients with chronic hepatitis B virus (HBV) infection with negative hepatitis B e antigen (HBeAg) and treated with nucleoside (acid) analogs (NA).

Study Start Date: Oct. 30

Study Type: INTERVENTIONAL

Condition: HBV (Hepatitis B Virus)

Intervention: DRUG: YKYY013

Drug: YKYY013 Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

DRUG: YKYY0...